Nuclera helps accelerate understanding of COVID-19

We are proud to share the news that Nuclera has been working with the University of Southampton to characterise ACE2, the main entry point of the SARS-CoV-2 coronavirus. Nuclera's protein scientist Dr Stephanie Reikine's collaborative work with the teams at Southampton has resulted in a peer-reviewed publication in the Feb 2020 issue of Nature Genetics. 
  
This study identified a novel isoform ACE2, which is selectively expressed in the airways - a primary location where respiratory viruses can infect the host. Importantly, work performed by Nuclera, using Cell-Free Protein Expression approaches, shows that this shorter, novel isoform can encode a detectable protein, and thus linking the genotype to function. Dr Reikine was able to show this faster, with less material, and in a more quantitative and multiplexed way compared to conventional methods.   

Read more